Focus on products eligible for the premium for promoting new drug development and addressing off-label drug use, as well as new products
First written in FY2020-Q2. 9 of 12 entries say "Advanced", first in FY2020. Latest entry: 2026-08-06.
1 other company's latest entry also says "Advanced".
- 2026-08-06AdvancedEarnings
「In the pharmaceutical wholesale business, although the drug price revision had a slightly negative impact, sales increased as a result of efforts including focusing on sales of products covered by the innovative new drug price maintenance system, particularly anticancer drugs.」
States that focusing on products eligible for the new drug creation premium and related programs contributed to higher sales in the pharmaceutical wholesale business despite the negative impact of the drug price revision. - FY2026AdvancedAnnual report
「This was attributable to growth in sales resulting from the company’s focus on products eligible for the new drug creation incentive, centered on anticancer drugs, and on influenza vaccines.」
The company’s focus on products eligible for the new drug creation incentive and other products is cited as a factor behind the increase in consolidated sales to ¥610,497 million. - FY2025AdvancedAnnual report
「In addition to growth in sales of test kits and treatments driven by the influenza outbreak, sales growth in products eligible for the new drug creation incentive, mainly anticancer drugs, as well as cervical cancer vaccines and a new COVID-19 vaccine introduced in October, exceeded the decline in other sales, resulting in higher revenue.」
The company reports that its focus on products eligible for the new drug creation incentive, originator products and vaccines contributed to pharmaceutical wholesale business sales of ¥564,614 million and segment profit of ¥5,163 million. - FY2025-H1AdvancedAnnual report
「In the pharmaceutical wholesale business during the interim consolidated accounting period, revenue increased slightly despite the negative effects of drug price revisions and declines in sales of COVID-19 treatments and test kits recorded in the same period of the previous year, as well as revenue from contracted COVID-19 vaccine delivery services. Sales of products eligible for the new drug creation incentive, centered on anticancer drugs, originator products, cervical cancer vaccines, and new COVID-19 vaccines scheduled to become available in October, exceeded the decline in revenue.」
As sales of COVID-19-related products and contracted services declined, sales of products eligible for the new drug creation incentive, centered on anticancer drugs, originator products and cervical cancer vaccines, exceeded the decline in revenue. - FY2024-Q3AdvancedAnnual report
「In the pharmaceutical wholesale business during the cumulative consolidated period through the third quarter, sales of anticancer drugs, COVID-19 treatments and influenza treatments grew more than expected and exceeded the decline in revenue, resulting in a slight increase in revenue despite the negative effects of drug price revisions, the suspension of products handled from certain manufacturers, and declining sales of COVID-19-related test reagents and equipment.」
The company reports that growth in sales of anticancer drugs, COVID-19 treatments and influenza treatments exceeded the decline in revenue despite the negative effects of drug price revisions and other factors. - FY2024-Q2AdvancedAnnual report
「In the pharmaceutical wholesale business during the cumulative consolidated period through the second quarter, revenue increased despite the negative effects of drug price revisions, the suspension of products handled from certain manufacturers, and declining sales of COVID-19-related test reagents and equipment. Sales of COVID-19 treatments and other products grew by more than the decline in revenue. As a result, sales were ¥277,201 million, compared with ¥273,830 million in the same period of the previous year, and segment operating profit was ¥2,640 million, compared with ¥1,393 million.」
Despite the negative effects of drug price revisions and the suspension of products handled from certain manufacturers, growth in sales of COVID-19 treatments and other products exceeded the decline in revenue, resulting in higher sales and profit in the pharmaceutical wholesale business. - FY2024-Q1AdvancedAnnual report
「In the pharmaceutical wholesale business during the consolidated cumulative period under review, sales of products eligible for the new drug creation incentive, centered on anticancer drugs and COVID-19 treatments, grew and exceeded the decline in sales of related products such as COVID-19 test kits. This more than offset the negative effects of drug price revisions and the suspension of products handled from certain manufacturers, resulting in a slight increase in revenue.」
Despite the negative effects of drug price revisions and the suspension of products handled from certain manufacturers, sales of products eligible for the new drug creation incentive, centered on anticancer drugs and COVID-19 treatments, grew and exceeded the decline in related-product sales. - FY2023-Q2RestatedAnnual report
「The company focused mainly on products eligible for the new drug creation incentive and various vaccines, particularly influenza vaccines, while sales of medical equipment and clinical testing reagents related to COVID-19 also remained firm. As a result, sales grew beyond the previous-year level.」
The company continued to focus on products eligible for the new drug creation incentive, various vaccines, and COVID-19-related medical equipment and clinical testing reagents, and reports that sales exceeded the previous-year level. - FY2023-Q1AdvancedAnnual report
「Sales of prescription drugs, mainly products eligible for the new drug creation incentive, grew primarily in the hospital market.」
Sales to the hospital market, centered on products eligible for the new drug creation incentive, grew, resulting in pharmaceutical wholesale business sales of ¥135,193 million and segment profit of ¥389 million. - FY2020AdvancedAnnual report
「The company focused on products eligible under the incentives for promoting new drug creation and resolving off-label drug use, as well as on new products. In particular, it emphasized sales of antineoplastic and specialty drugs to hospitals, centered on “cancer liaisons” developed internally.」
To address declining sales of long-listed products, the company continued to focus on products eligible under the incentive scheme and on new, antineoplastic and specialty drugs, generating sales of ¥533,412 million and segment profit of ¥3,164 million in the pharmaceutical wholesale business. - FY2020-Q3RestatedAnnual report
「In this environment, the company focused on products eligible under the incentives for promoting new drug creation and resolving off-label drug use, as well as on new products.」
Amid continued declines in sales of long-listed products, the company continues its sales initiatives focused on products eligible under the incentive scheme and on new products. - FY2020-Q2First statedAnnual report
「In this environment, the company focused on products eligible under the incentives for promoting new drug creation and resolving off-label drug use, as well as on new products.」
Amid continued declines in sales of long-listed products, the company describes specific sales initiatives focused on products eligible under the incentive scheme and on new products.